#hotoffthepress
In this #CME review, the authors report the pivotal results of the INDIGO clinical trial of vorasidenib versus placebo for patients with IDH mutant low-grade glioma ⬇️
www.sciencedirect.co...
In this #CME review, the authors report the pivotal results of the INDIGO clinical trial of vorasidenib versus placebo for patients with IDH mutant low-grade glioma ⬇️
www.sciencedirect.co...
September 24, 2026 at 9:00 AM
#hotoffthepress
In this #CME review, the authors report the pivotal results of the INDIGO clinical trial of vorasidenib versus placebo for patients with IDH mutant low-grade glioma ⬇️
www.sciencedirect.co...
In this #CME review, the authors report the pivotal results of the INDIGO clinical trial of vorasidenib versus placebo for patients with IDH mutant low-grade glioma ⬇️
www.sciencedirect.co...
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment helps people with newly diagnosed IDH mutated grade 3 astrocytoma, a brain cancer. https://bit.ly/Brain2026 #clinicaltrials #oncsky
September 21, 2026 at 10:00 AM
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment helps people with newly diagnosed IDH mutated grade 3 astrocytoma, a brain cancer. https://bit.ly/Brain2026 #clinicaltrials #oncsky
The first Australian participant has been enrolled in the global VIGOR trial, sponsored by ONJCRI in collaboration with COGNO in Australia.
The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.
➡️ https://ow.ly/SnyR50ZMpoj
#VIGORTrial #Glioma
The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.
➡️ https://ow.ly/SnyR50ZMpoj
#VIGORTrial #Glioma
September 16, 2026 at 11:00 PM
The first Australian participant has been enrolled in the global VIGOR trial, sponsored by ONJCRI in collaboration with COGNO in Australia.
The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.
➡️ https://ow.ly/SnyR50ZMpoj
#VIGORTrial #Glioma
The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.
➡️ https://ow.ly/SnyR50ZMpoj
#VIGORTrial #Glioma
⭐ Congratulations to @jingyiwu.bsky.social for receiving a research grant from @thevfoundation.bsky.social!
This research aims to discover what makes a #glioma tumor resist the FDA-approved IDH inhibitor vorasidenib and whether a secondary therapy can improve its response to treatment.
This research aims to discover what makes a #glioma tumor resist the FDA-approved IDH inhibitor vorasidenib and whether a secondary therapy can improve its response to treatment.
August 31, 2026 at 5:00 PM
⭐ Congratulations to @jingyiwu.bsky.social for receiving a research grant from @thevfoundation.bsky.social!
This research aims to discover what makes a #glioma tumor resist the FDA-approved IDH inhibitor vorasidenib and whether a secondary therapy can improve its response to treatment.
This research aims to discover what makes a #glioma tumor resist the FDA-approved IDH inhibitor vorasidenib and whether a secondary therapy can improve its response to treatment.
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #oncsky #medsky
August 24, 2026 at 1:00 PM
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #oncsky #medsky
CU Anschutz Cancer Center's Peter E. Fecci, MD, PhD, spoke with @onclive.bsky.social about recent therapeutic advances and ongoing challenges in the management of glioblastoma ⬇️
https://www.onclive.com/view/dr-fecci-on-immunotherapy-research-innovations-in-glioblastoma
https://www.onclive.com/view/dr-fecci-on-immunotherapy-research-innovations-in-glioblastoma
Dr Fecci on Immunotherapy Research Innovations in Glioblastoma | OncLive
Fecci began by noting the importance of the IDH inhibitor class, including vorasidenib (Voranigo).
www.onclive.com
August 7, 2026 at 6:20 PM
CU Anschutz Cancer Center's Peter E. Fecci, MD, PhD, spoke with @onclive.bsky.social about recent therapeutic advances and ongoing challenges in the management of glioblastoma ⬇️
https://www.onclive.com/view/dr-fecci-on-immunotherapy-research-innovations-in-glioblastoma
https://www.onclive.com/view/dr-fecci-on-immunotherapy-research-innovations-in-glioblastoma
NEW PODCAST: #PBS Update August 2026
@craigunderhill.bsky.social + Rachael Babin discuss #vorasidenib, #selpercatinib and #tafasitamab. Shout out to Jim Whittle, Katy Peters & #ArchieGoodwyn #glioma #lymphoma #thyroidcancer #IDH @dukecancer.bsky.social @petermaccc.bsky.social Listen now: t.ly/jkDnJ
@craigunderhill.bsky.social + Rachael Babin discuss #vorasidenib, #selpercatinib and #tafasitamab. Shout out to Jim Whittle, Katy Peters & #ArchieGoodwyn #glioma #lymphoma #thyroidcancer #IDH @dukecancer.bsky.social @petermaccc.bsky.social Listen now: t.ly/jkDnJ
August 5, 2026 at 11:45 PM
NEW PODCAST: #PBS Update August 2026
@craigunderhill.bsky.social + Rachael Babin discuss #vorasidenib, #selpercatinib and #tafasitamab. Shout out to Jim Whittle, Katy Peters & #ArchieGoodwyn #glioma #lymphoma #thyroidcancer #IDH @dukecancer.bsky.social @petermaccc.bsky.social Listen now: t.ly/jkDnJ
@craigunderhill.bsky.social + Rachael Babin discuss #vorasidenib, #selpercatinib and #tafasitamab. Shout out to Jim Whittle, Katy Peters & #ArchieGoodwyn #glioma #lymphoma #thyroidcancer #IDH @dukecancer.bsky.social @petermaccc.bsky.social Listen now: t.ly/jkDnJ
Our preclinical data suggest that sequencing vorasidenib and chemoradiation therapies may benefit patients, providing empirical evidence relevant to a pressing clinical question. (6/7)
August 5, 2026 at 6:12 PM
Our preclinical data suggest that sequencing vorasidenib and chemoradiation therapies may benefit patients, providing empirical evidence relevant to a pressing clinical question. (6/7)
How does first-line vorasidenib therapy affect efficacy of next-line chemoradiation? This issue is increasingly relevant for patient care but remains unresolved. Modeling therapy sequencing in mice revealed that prior vorasidenib treatment improves the efficacy of subsequent chemoradiation. (4/7)
August 5, 2026 at 6:12 PM
How does first-line vorasidenib therapy affect efficacy of next-line chemoradiation? This issue is increasingly relevant for patient care but remains unresolved. Modeling therapy sequencing in mice revealed that prior vorasidenib treatment improves the efficacy of subsequent chemoradiation. (4/7)
One barrier to progress is that there are few models of glioma that respond to mutant IDH inhibition. Shi and Calvo Fernández et al. tackled this issue by showing that a genetic mouse model of IDH-mutant glioma responded to vorasidenib. (2/7)
August 5, 2026 at 6:12 PM
One barrier to progress is that there are few models of glioma that respond to mutant IDH inhibition. Shi and Calvo Fernández et al. tackled this issue by showing that a genetic mouse model of IDH-mutant glioma responded to vorasidenib. (2/7)
The dual mutant IDH1/IDH2 inhibitor vorasidenib was recently approved by the FDA and other regulatory agencies to treat low-grade gliomas as a first-line therapy. This has prompted key questions related to how vorasidenib interacts with conventional glioma therapies. (1/7)
August 5, 2026 at 6:12 PM
The dual mutant IDH1/IDH2 inhibitor vorasidenib was recently approved by the FDA and other regulatory agencies to treat low-grade gliomas as a first-line therapy. This has prompted key questions related to how vorasidenib interacts with conventional glioma therapies. (1/7)
ONLINE NOW in @science.org Translational Medicine from CRI's McBrayer Lab: www.science.org/doi/10.1126/.... Full 🧵 in comments ⬇️ #relentlessdiscovery 🧪
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma
A genetic mouse model of IDH-mutant glioma responds to mutant IDH inhibitor (mIDHi) and shows that prior mIDHi treatment improves response to chemoradiation.
www.science.org
August 5, 2026 at 6:05 PM
ONLINE NOW in @science.org Translational Medicine from CRI's McBrayer Lab: www.science.org/doi/10.1126/.... Full 🧵 in comments ⬇️ #relentlessdiscovery 🧪
And to be clearer the surgery was for the biopsy, they just need to do genetic testing to figure out just what kind of tumor they're dealing with. Fingers crossed for something that responds well to Vorasidenib.
July 22, 2026 at 7:34 AM
And to be clearer the surgery was for the biopsy, they just need to do genetic testing to figure out just what kind of tumor they're dealing with. Fingers crossed for something that responds well to Vorasidenib.
#NUVB Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
https://www.stocktitan.net/news/NUVB/nuvation-bio-announces-positive-updated-phase-2-data-and-expansion-rjhe8taevj61.html
https://www.stocktitan.net/news/NUVB/nuvation-bio-announces-positive-updated-phase-2-data-and-expansion-rjhe8taevj61.html
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.. New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.. The company will initiate two new studies to evaluate safusidenib across the broader landscape of IDH1- mutant glioma: a pivotal...
www.stocktitan.net
July 20, 2026 at 12:00 PM
#NUVB Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
https://www.stocktitan.net/news/NUVB/nuvation-bio-announces-positive-updated-phase-2-data-and-expansion-rjhe8taevj61.html
https://www.stocktitan.net/news/NUVB/nuvation-bio-announces-positive-updated-phase-2-data-and-expansion-rjhe8taevj61.html
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials
July 20, 2026 at 12:00 PM
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials
Just about time to take Vorasidenib and lie down. Closing out Thursday properly
youtu.be/F0DdZphhCnw?...
youtu.be/F0DdZphhCnw?...
1973 - Led Zeppelin - Houses Of The Holy [FULL ALBUM]
YouTube video by Lassa Vakk
youtu.be
July 3, 2026 at 12:54 AM
Just about time to take Vorasidenib and lie down. Closing out Thursday properly
youtu.be/F0DdZphhCnw?...
youtu.be/F0DdZphhCnw?...
O medicamento Voranigo (vorasidenib) obteve autorização para ser utilizado em meio hospitalar.
Saiba mais: 🔗https://swki.me/WxViyrCo
#infarmed #medicamentos #financiamentopublico #voranigo
Saiba mais: 🔗https://swki.me/WxViyrCo
#infarmed #medicamentos #financiamentopublico #voranigo
June 19, 2026 at 2:31 PM
O medicamento Voranigo (vorasidenib) obteve autorização para ser utilizado em meio hospitalar.
Saiba mais: 🔗https://swki.me/WxViyrCo
#infarmed #medicamentos #financiamentopublico #voranigo
Saiba mais: 🔗https://swki.me/WxViyrCo
#infarmed #medicamentos #financiamentopublico #voranigo
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials
June 18, 2026 at 10:00 PM
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials
FDA-approved in Aug 2024 for grade 2 astrocytoma and oligodendroglioma, vorasidenib is the first brain-penetrant dual IDH1/2 inhibitor. It reduces 2-hydroxyglutarate, partially restores cellular differentiation, and may overcome resistance linked to single-target IDH mutations.
June 7, 2026 at 8:28 AM
FDA-approved in Aug 2024 for grade 2 astrocytoma and oligodendroglioma, vorasidenib is the first brain-penetrant dual IDH1/2 inhibitor. It reduces 2-hydroxyglutarate, partially restores cellular differentiation, and may overcome resistance linked to single-target IDH mutations.
Servier's VORANIGO® Shows Promising Long-Term Benefits in Extended INDIGO Trial Results#None#Chicago#Servier#Glioma#VORANIGO
Servier's VORANIGO® Shows Promising Long-Term Benefits in Extended INDIGO Trial Results
Servier unveils extended results from the Phase 3 INDIGO trial, showing VORANIGO® (vorasidenib) offers significant long-term benefits for glioma patients. Profound improvements and robust data presented at ASCO 2026.
third-news.com
May 31, 2026 at 9:40 PM
Tumori cerebrali rari: glioma IDH-mutato, nasce in Piemonte il nuovo modello di presa in carico
Una rivoluzione che parte dalla cura farmacologica e continua con il modello della presa in carico dei pazienti: una nuova terapia mirata, vorasidenib, già disponibile in Europa e per la quale si…
Una rivoluzione che parte dalla cura farmacologica e continua con il modello della presa in carico dei pazienti: una nuova terapia mirata, vorasidenib, già disponibile in Europa e per la quale si…
Tumori cerebrali rari: glioma IDH-mutato, nasce in Piemonte il nuovo modello di presa in carico
Una rivoluzione che parte dalla cura farmacologica e continua con il modello della presa in carico dei pazienti: una nuova terapia mirata, vorasidenib, già disponibile in Europa e per la quale si attende in Italia il via libera di Aifa, sta cambiando la storia clinica dei gliomi di basso grado con mutazione nei geni IDH. Per la prima volta, infatti, una terapia orale consente di rallentare in modo significativo la progressione della malattia, ritardando il ricorso a radio e chemioterapia e preservando più a lungo qualità della vita, autonomia e funzioni cognitive dei pazienti.
www.saluteh24.com
May 29, 2026 at 9:17 AM
Tumori cerebrali rari: glioma IDH-mutato, nasce in Piemonte il nuovo modello di presa in carico
Una rivoluzione che parte dalla cura farmacologica e continua con il modello della presa in carico dei pazienti: una nuova terapia mirata, vorasidenib, già disponibile in Europa e per la quale si…
Una rivoluzione che parte dalla cura farmacologica e continua con il modello della presa in carico dei pazienti: una nuova terapia mirata, vorasidenib, già disponibile in Europa e per la quale si…